NCT00056797View on ClinicalTrials.gov

Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC HIV vaccine (vCP1452)

DRUG

Interleukin-2

Trial Locations (1)

10021

NY Presbyterian Weill Cornell Medical Center, New York

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00056797 - Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV | Biotech Hunter | Biotech Hunter